Vigil Neuroscience Reports Fourth Quarter and Full Year

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment...

Related Keywords

Montreal ,Quebec ,Canada ,Petra Kaufmann ,Ivana Magov ,Megan Mcgrath ,Leah Gibson ,Development Rd Expenses ,Exchange Commission ,Vigil Neuroscience Inc ,Investor Relations Corporate Communications ,Nasdaq ,Kaufmann ,Chief Medical Officer ,Vigil Neuroscience ,Chief Executive Officer ,Anticipated Milestones ,Monoclonal Antibody ,Montreal Cognitive Assessment ,Oral Small Molecule ,Chief Medical ,Quarterly Report ,Annual Report ,Investor Relations ,Corporate Communications ,Nasdaq Vigl ,Nc ,